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actors including advanced age, prolonged duration of the lesion,
ack of fever and absence of air bronchograms should raise the sus-
icion of TB. Previous exposure to a FQ for >10 days in patients
ith TB is associated with the emergence of FQ-resistant M. tuber-
ulosis isolates. However, rates of M. tuberculosis isolates with
Q resistance are signiﬁcantly higher amongst multidrug-resistant
. tuberculosis isolates than amongst susceptible isolates. Conse-
uently, in countries with TB endemicity, a short-course (5-day)
egimen of a respiratory FQ is still recommended as empirical ther-
py for CAP patients if the patient is at low risk for TB.
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luoroquinolones: A role in CAP and TB
. Grossman
Credit Valley Hospital, Mississauga, Canada
Fluoroquinolones are used widely for the treatment of LRTIs.
he ATS/IDSA guidelines for CAP recommended them as use-
ul choices in many clinical scenarios especially for hospitalized
atients. Concerns have been raised that using ﬂuoroquinolones
or the management of LRTIs will destroy the value of this class
or use particularly in MDR-TB. Arguments center on the notion
hat ﬂuoroquinoloneswillmask the clinical features of TB, delaying
iagnosis and enhancing widespread dissemination. They further
ostulate that the yield of culture-negative TB will increase and
hat, with increasing use of ﬂuoroquinolones, ﬂuoroquinolone-
esistant TB will become increasingly prevalent. Many patients
nfected with TB present with LRTI symptoms and a lung inﬁltrate.
brief treatment course with a ﬂuoroquinolone rarely produces a
apid clinical recovery. Most patients with TB, even when treated
ppropriately, have a very slow radiographic response and often
eteriorate initially. In contrast, bacterial pneumonia usually has
rapid radiographic response especially in previously healthy
oung adults. Studies trying to document delayed diagnosis when
uoroquinolones have been used, have been unable to mount a
ersuasive case. There is no evidence that patients initially treated
ith a ﬂuoroquinolone are more likely to have culture-negative
B. Multiple studies to date have documented a very low rate
f ﬂuoroquinolone-resistant TB throughout the world. There has
een no relationship between prior ﬂuoroquinolone exposure and
he emergence of resistance. The most persuasive relationship
s between ﬂuoroquinolone resistance and multi-drug resistance.
ndiandata suggest amorewidespreadproblemexists but thatmay
ave more to do with ease of availability of all antibiotics without
hysician supervision in that country. If a patient presents with
clinical illness suggestive of TB, ﬂuoroquinolones should not be
sed asmonotherapy. But even if used inpatients ultimately shown
o have TB, a short exposure to a potent ﬂuoroquinolone is unlikely
o delay diagnosis or lead to the emergence of bacterial resistance.
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Fluoroquinolones in TB: The future
S.H. Gillespie
University of St. Andrews, St. Andrews, United Kingdom
Moxiﬂoxacin has been demonstrated to have excellent activity
against Mycobacterium tuberculosis in vitro and in mouse models.
This encouraging activity against this important human pathogen
is combinedwith a pharmacokinetic proﬁle that permits once a day
dosing. The results of several mouse model studies have suggested
that substitution ofmoxiﬂoxacin for ethambutol or isoniazidmight
allow treatment duration to be shortened to four months. This has
been supported by clinical phase II studies.
A phase III pivotal trial (REMoxTB), is now underway to test reg-
imens built on moxiﬂoxacin and the results of these studies are
eagerly awaited. The test regimens substitute either ethambutol
or isoniazid with moxiﬂoxacin and offer the best chance of reduc-
ing current treatment duration from six months to four, the ﬁrst
improvement in TB treatment for more than ﬁfty years. The trial is
being performed at multiple sites in Africa and Asia.
Fluoroquinolonesalsohavean important role toplay in theman-
agementofpatientswithdrug toxicity aswell asbeingan important
part of the treatment ofmultiple drug resistance forwhich they are
recommended by a number of national and international bodies.
Nevertheless, well controlled clinical trials of the role of ﬂuoro-
quinolones are still required in the management of multiple drug
resistance are required. Further studies investigating regimens that
combine moxiﬂoxacin with repurposed and new agents are now
entering the clinical trial phase.
Resistance to ﬂuoroquinolones is a growing concern due to
the increasing frequency with which resistant strains are being
reported. This emphasises the importance of improving diagnosis
of respiratory tract infection, good antibiotic stewardship and the
use of the modern ﬂuoroquinolones that are least likely to select
for resistance.
http://dx.doi.org/10.1016/j.ijid.2012.05.025
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State of the science: Antiretroviral treatment for prevention
B. Hirschel
Geneva University Hospital, Geneva, Switzerland
“No virus, no transmission.” In the absence of treatment,
the viral load (the quantity of virus present in blood and sex-
ual secretions) is the strongest predictor of HIV transmission
with unprotected sex, or from infected mother to child. Effective
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reatment lowers viral load to undetectable levels. Two controlled,
rospective studies in heterosexual couples have shown that treat-
ent virtually eliminates the risk of transmission.
Thus, if one could identify and treat all HIV-infected people
mmediately after infection, the HIV/AIDS epidemic would even-
ually disappear. In reality, not all people get tested, especially
hen they fear stigma and discrimination. In consequence not all
IV-infected individuals are known. This is particularly true for
he recently infected, who are also the most infectious. Not all of
hose HIV-positive individuals for whom the diagnosis is known
ave access to therapy, agree to be treated, or are taking therapy
ffectively. Someon effective treatmentwill stop, and in others, the
evelopment of resistance will lead to treatment failure.
In places like Vancouver and San Francisco, the majority of HIV-
ositive individuals are now under treatment, and the incidence of
ew HIV infections has recently fallen. However, correlation does
ot necessarily imply causation: In fact, the preventive potential
f anti-HIV drugs is unknown. Several large studies are starting in
012, using cluster randomization: a number of communities are
andomized to either receive the “test-and-treat” approach or con-
inue as before. Repeatedwaves of testingwould preciselymeasure
he incidence of HIV infection. Such trials face formidable logistical,
ractical and ethical obstacles.
Furthermore, resources are limited: should we provide drugs
o asymptomatic HIV-infected individuals without indication for
reatment according to guidelines in order to prevent HIV trans-
ission at the risk of diverting funding from sick patients in urgent
eed? Without deﬁnitive data, the intuitive appeal of “test-and-
reat” is unlikely to translate into action on a global scale. In the
eantime, based on the available evidence, we must strive to
rovide treatment to all those in medical need under the cur-
ent medical guidelines. This will contribute to a decrease in HIV
ransmissionwhile “test-and-treat” is fully explored in prospective
rials.
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reatment 2.0 and antiretroviral therapy for prevention
. Kato
WHO Vietnam, Hanoi, Viet Nam
At the end of 2010, 6.65million peoplewere receiving antiretro-
iral therapy (ART) globally, while more than 10 million people in
eed have not yet accessed the treatment. In 2011, United Nations
eneral Assembly set the global target to provide ART to 15 million
eople by 2015.
UNAIDS/WHO-proposed “Treatment 2.0” initiative aims to cat-
lyze the next phase of ART scale-up, through radical simpliﬁcation
f HIV treatment. Treatment 2.0 is designed to achieve and sustain
niversal access and maximize the preventive beneﬁts of ART by
mproving the efﬁciency and impact of HIV care and treatment pro-
rams in resource-limited countries. It ﬁve priority areas include:
) Optimize drug regimens, 2) Promote diagnostics using point of
are and other simpliﬁed technologies, 3) Reduce costs; 4) Adapt
elivery systems, and 5) Mobilize communities. Several countries
tarted to adopt Treatment 2.0 approaches.nfectious Diseases 16S (2012) e2–e157 e9
In Viet Nam, the Ministry of Health (MOH) initiated Treatment
2.0pilot in twoprovinces.HIV testingandcounseling (HTC)andART
delivery is being decentralized to primary health care stations. HTC
andART are also integrated into amethadonemaintenance therapy
(MMT) center. Peer educatorsworking for HIV prevention outreach
are trained for treatment literacy and supported to refer their peers
for repeated HIV testing. Rapid tests, once-day ﬁxed-dose combi-
nation ARV regimens and point-of-care CD4 technologies are being
introduced to simplify the procedures from HIV diagnosis to ART
initiation and life-long treatment.
Based the compelling evidence suggesting ART prevents HIV
transmission, WHO released the Guidelines on Couples HTC and
ART for treatment and prevention in HIV serodiscordant couples in
April 2012. Five Asian countries are now planning implementation
studies to operationalilze early ART for treatment and prevention,
while adapting the WHO Guidelines. ART has being proved to be a
powerful interventions to be included as part of the combination
HIV prevention framework.
To improve ART effectiveness at the population level, expanded
HTC to help people to know their HIV status, optimize drug reg-
imens, promote a functional continuum of prevention and care,
and effectively address themajor access and retention barriers (e.g.
stigma, discrimination, punitive laws) are essential.
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State of the Science – HIV Pre-Exposure Prophylaxis (PrEP)
S. Chariyalertsak
Research Institute for Health Sciences (RIHES), Chiang Mai, Thailand
HIV remains a signiﬁcant global health challenge with an esti-
mated 2.6 million people newly infected in 2009. The need of
effective HIV prevention interventions are very crucial for con-
trolling the epidemic especially among high-risk populations.
Pre-exposure prophylaxis (PrEP) refers to the use of antiretroviral
(ARV) medication either oral or topical by HIV-uninfected persons
prior to HIV exposure and continue during period of risk to prevent
HIV acquisition. The success of ARV drugs in preventing HIV trans-
mission from mothers to infants and in decreasing seroconversion
when given to adults shortly afterHIV exposure stimulated interest
in the concept of PrEP. An effective PrEP could provide an additional
safety net to sexually active persons at risk, when combined with
other HIV effective prevention strategies. Many clinical researches
are ongoing with ARV-based prevention or PrEP in different at risk
population across theworld including rectalmicrobicides andARV-
based vaginal ring. In the past few years, of seven PrEP trials with
available HIV endpoints, three different products have been tested
: tenoﬁvir 1% vaginal gel, oral tenofovirdisoproxilfumarate (TDF)
tablets, and TDF/emtricitabine (TDF/FTC or Truvada) tablets. All
found the products to be safe, and four (CAPRISA004 as topical
gel; and iPrEX, Partners PrEP, and TDF2 as oral PrEP) demonstrated
moderate effectiveness for HIV prevention when combined with
other HIV prevention strategies. On the other hand, the assess-
ment of oral Truvada in the FEM-PrEP study and of oral and vaginal
tenofovir in the VOICE study were stopped for futility by DSMB
in 2011. These discrepant results of PrEP studies are perplexing
